Accenture plc (ACN) Stock Price & Analysis
Accenture plc (ACN) closed at USD 258.74 on Thursday, October 22, 2026, up 7.69% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 240.26; the Oct 22, 2026 session ranged USD 239.33–259.39 on volume of 8,296,880 shares. Market capitalization is $158.33B, with a 52-week range of USD 118.15–291.09 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 08:35 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ACN.md
Latest Earnings Results (ACN)
| Fiscal period | EPS (reported) | Revenue | Released | Source |
|---|---|---|---|---|
| Q4 2026 | $3.29 (GAAP diluted) | $18.68B | Oct 1, 2026, 6:42:03 AM ET · on Nexqual +34 seconds | SEC 8-K filing |
Reported actuals captured by Nexqual from SEC 8-K filings and company press releases; each figure confirmed by two independent extraction methods.
Key facts (ACN)
- Last four reported quarters (through Aug 31, 2026): revenue $74.2B, net income $8.37B (11.3% margin), free cash flow $11.6B (SEC filings).
- Valuation: P/E 18.9x (avg 21.8x at the last 3 fiscal year-ends), EV/EBITDA 13.0x, net cash $2.73B.
- 2 of 80 tracked superinvestors hold ACN (13F, Q2 2026): 1 new, 0 added, 1 reduced, 0 unchanged.
- Analysts: Hold (mean 2.56 on a 1–5 scale) (27 analysts), mean target USD 227.07 (range 163–280).
- Total return with dividends: 1Y +6.6% vs S&P 500 +14.9%; 5Y -20.1% vs S&P 500 +80.3%.
- Next earnings: 2026-12-17, EPS estimate USD 3.95, revenue estimate $19.4B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ACN)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $61.6B | $64.1B | $64.9B | $69.7B | $74.2B | $74.2B |
| Gross profit | $19.7B | $20.7B | $21.2B | $22.2B | $23.8B | — |
| Operating income | $9.37B | $8.81B | $9.60B | $10.2B | $11.4B | $11.4B |
| Net income | $6.88B | $6.87B | $7.26B | $7.68B | $8.37B | $8.37B |
| EPS (diluted) | $10.71 | $10.77 | $11.44 | $12.15 | $13.56 | — |
| Free cash flow | $8.82B | $9.00B | $8.61B | $10.9B | $11.6B | $11.6B |
| Gross margin | 32.0% | 32.3% | 32.6% | 31.9% | 32.0% | — |
| Operating margin | 15.2% | 13.7% | 14.8% | 14.7% | 15.4% | 15.4% |
| Net margin | 11.2% | 10.7% | 11.2% | 11.0% | 11.3% | 11.3% |
| Revenue growth | +21.9% | +4.1% | +1.2% | +7.4% | +6.5% | — |
| Cash + short-term investments | $7.89B | $9.05B | $5.01B | $11.5B | $12.8B | — |
| Total debt | $55.1M | $148M | $1.02B | $5.15B | $10.1B | — |
Fiscal years end Aug. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Aug 31, 2026) (ACN)
P/E 18.9x · P/S 2.1x · EV/EBITDA 13.0x · EV/Sales 2.1x · P/FCF 13.6x · P/B 5.0x · FCF yield 7.34% · Earnings yield 5.28% · Buyback yield (TTM) 4.75% · Net cash $2.73B · EV $156B
P/E at fiscal year-ends: Aug 2026 14.0x, Aug 2025 21.4x, Aug 2024 29.9x.
Superinvestors (SEC 13F-HR, Q2 2026) (ACN)
2 of 80 tracked investors hold ACN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Torray Funds | 2.81% | $20.9M | New position | |
| Jensen Investment Management | 0.16% | $6.5M | Reduced -10.4% |
Analysts (ACN)
Consensus Hold (mean 2.56 on a 1–5 scale), 27 analysts; mean target USD 227.07 (low 163, high 280).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Baird | Downgrade | Outperform → Neutral | $245 → $252 |
| 2026-10-15 | TD Cowen | Target raised | Hold | $193 → $201 |
| 2026-10-15 | Susquehanna | Target raised | Neutral | $210 → $230 |
| 2026-10-06 | Mizuho | Target raised | Outperform | $226 → $241 |
| 2026-10-02 | Goldman Sachs | Target raised | Buy | $230 → $260 |
| 2026-10-02 | Truist Securities | Target raised | Hold | $150 → $220 |
| 2026-10-02 | Wells Fargo | Target raised | Equal-Weight | $194 → $210 |
| 2026-10-02 | TD Cowen | Target raised | Hold | $173 → $193 |
| 2026-10-02 | RBC Capital | Target raised | Outperform | $175 → $240 |
| 2026-10-02 | Evercore ISI Group | Target raised | Outperform | $180 → $250 |
| 2026-10-02 | Guggenheim | Reiterated | Neutral | |
| 2026-10-02 | Argus Research | Target raised | Buy | $220 → $260 |
Total return (dividends reinvested) (ACN)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +6.6% | -20.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +6.6% | -4.4% |
| Volatility (annualized) | 49.6% | 33.3% |
| Max drawdown | -56.5% (Jan 2026→Jun 2026) | -67.0% (Dec 2021→Jun 2026) |
ACN revenue by business segment (quarter ended Aug 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Americas | $9.43B | 50.5% | +7.1% |
| EMEA | $6.58B | 35.2% | +6.2% |
| Asia Pacific | $2.67B | 14.3% | +2.7% |
| Total revenue | $18.68B | 100% | — |
ACN revenue by product line (quarter ended Aug 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Managed Services | $9.40B | 50.3% | +6.5% |
| Consulting Revenue | $9.28B | 49.7% | +5.8% |
| Total revenue | $18.68B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
ACN suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Accenture Canada Holdings | “Most of our pre-incorporation partners who received Accenture Canada Holdings Inc. exchangeable shares in connection with our transition to a corporate structure received a corresponding number of Accenture plc Class X ordinary shares.” |
Quoted from the company's 10-K filed Oct 16, 2026.
Companies that name ACN in their SEC reports
| Relationship to ACN | Company | Filing | Sentence |
|---|---|---|---|
| competitor | CLPS Inc (CLPS) | 20-F Oct 16, 2026 | “To date, we do not typically compete directly with the larger global consulting and outsourcing firms, such as Accenture, Capgemini, Hewlett-Packard and IBM, who are typically engaged in conjunction with large global projects.” |
| partner | Hub Cyber Security Ltd. (HUBCZ) | 20-F Jul 17, 2026 | “and Chief Information Officer at Apotex Inc. Prior to that, Mr. Bibas was a Partner at Accenture, where he led the Canadian High-Tech” |
| partner | Dynatrace, Inc. (DT) | 10-K May 20, 2026 | “We work closely with a number of strategic GSIs, including Accenture, Atos, Deloitte, DXC, and Kyndryl, to help customers digitally transform their businesses and reduce cloud complexity.” |
| competitor | FORMULA SYSTEMS (1985) LTD (FORTY) | 20-F May 13, 2026 | “governance, risk and compliance (GRC), Matrix competes with large global corporations such as IBM, Accenture and Oracle, as well as the” |
| competitor | Nvni Group Ltd (NVNI) | 20-F Apr 30, 2026 | “Principal competitors include Globant, Endava, EPAM Systems, Thoughtworks, Tata Consultancy Services, Infosys, Wipro, Accenture, IBM” |
| partner | nCino, Inc. (NCNO) | 10-K Mar 31, 2026 | “These partners (including Accenture, Deloitte, PwC, and West Monroe Partners, among others) assist in prospecting, marketing, co-selling, product evaluation/feedback, and implementation of our solutions and have helped support our new market and global expansion.” |
| partner | SailPoint, Inc. (SAIL) | 10-K Mar 19, 2026 | “We partner with many large and global system integrators including Accenture, Capgemini, Deloitte, KPMG, and PwC, as well as many regional system integrators.” |
| partner | Sprinklr, Inc. (CXM) | 10-K Mar 19, 2026 | “We work with agencies and partners across nine different partner categories, including System Integrators, Transformational partners and Resellers, which includes partners such as Microsoft, Accenture, Deloitte, Salesforce, SAP, ServiceNow, Adobe, Oracle and others.” |
| partner | DarioHealth Corp. (DRIO) | 10-K Mar 19, 2026 | “Prior to Chicago Pacific Partners, Mr. Leisure held senior management roles at Accenture, PricewaterhouseCoopers, Towers Perrin, Kaiser Foundation Health Plans and UnitedHealth Group.” |
| competitor | Science Applications International Corp (SAIC) | 10-K Mar 16, 2026 | “•diversified commercial providers that also provide U.S. government IT services, such as Accenture plc, AECOM, Amentum Holdings, Inc., Deloitte, and International Business Machines Corporation.” |
| competitor | Stagwell Inc (STGW) | 10-K Mar 13, 2026 | “Our Brands also face competition from consultancies, such as Accenture and Deloitte, tech platforms, media companies and other services firms that offer related services.” |
| partner | AMERICAN PUBLIC EDUCATION INC (APEI) | 10-K Mar 12, 2026 | “Earlier in her career, Ms. Selden spent 18 years at Accenture, including serving as the Managing Partner leading Accenture's North American West Consumer and Industrial Products group to significant growth.” |
| partner | MongoDB, Inc. (MDB) | 10-K Mar 11, 2026 | “We have also expanded our existing partnerships with independent software vendors and global systems integrators including IBM, Accenture, Infosys, Capgemini, Confluent, HCL, Wipro, Cognizant, Deloitte and Tata Consultancy Services.” |
| competitor | CI&T Inc (CINT) | 20-F Mar 11, 2026 | “Our primary competitors include technology transformation and software engineering service providers, such as Endava plc, Globant S.A, EPAM Systems Inc. and Thoughtworks Holding, Inc. Other competitors include traditional IT services companies, such as Accenture plc, Capgemini SE, Cognizant Technology Solutions Corporation and Tata Consultancy Services Limited.” |
| competitor | Rackspace Technology, Inc. (RXT) | 10-K Mar 6, 2026 | “•Traditional global IT systems integrators, such as Accenture, Atos, Capgemini, Cognizant, Deloitte, DXC Technology and Kyndryl, offer consulting and outsourcing, in a labor-intensive model, for large enterprise customers.” |
ACN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Nov 2026) | $3.95 | $3.99 | -1.0% | $19.41B | 21 |
| Next quarter (ends Feb 2027) | $3.15 | $3.16 | -0.3% | $18.82B | 21 |
| Current fiscal year (ends Aug 2027) | $14.66 | $14.66 | -0.0% | $77.43B | 28 |
| Next fiscal year (ends Aug 2028) | $15.89 | $15.79 | +0.6% | $81.36B | 26 |
ACN options: expected move
Options price a move of about ±14.4% (±$37.05) by Dec 18, 2026, which includes earnings on Dec 17, 2026; the earnings reaction alone is priced at about ±7.1%. Over the last 8 reports the stock moved ±5.8% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 46.1% | ±5.5% |
| Nov 6, 2026 | 14 | 43.6% | ±7.1% |
| Nov 13, 2026 | 21 | 42.8% | ±8.5% |
| Nov 20, 2026 | 28 | 42.6% | ±9.7% |
| Nov 27, 2026 | 35 | 41.0% | ±10.3% |
| Dec 4, 2026 | 42 | 39.9% | ±11.0% |
| Dec 18, 2026 | 56 | 45.5% | ±14.4% |
| Jan 15, 2027 | 84 | 43.4% | ±16.9% |
30-day implied volatility 40.5% vs 63.2% realized over the last 30 trading days. Put/call ratio (volume) 0.42. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 08:35 UTC)
| Price | USD 258.74 |
|---|---|
| Change | ▲ 7.69% (up) |
| Previous Close | USD 240.26 |
| Open | USD 242 |
| Day Range | USD 239.33 – 259.39 |
| 52-Week Range | USD 118.15 – 291.09 |
| Volume | 8,296,880 shares |
| Market Cap | $158.33B |
| Exchange | NYQ |
Technical Analysis (ACN)
Nexqual's technical model rates ACN "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 08:35 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 80.1 (overbought) |
| vs SMA50 | Above (USD 194.4) |
| MACD | 15.73 (positive) |
Analyst Ratings (ACN)
Wall Street analysts rate ACN "Hold" based on 27 analysts, with a mean price target of USD 227.07 (range USD 163–280), per Nexqual as of October 23, 2026 at 08:35 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 27 |
| Mean Target | USD 227.07 |
| High Target | USD 280 |
| Low Target | USD 163 |
| Buy / Hold / Sell | 10 / 17 / 0 |
Earnings (ACN)
| Next Earnings Date | 2026-12-17 |
|---|---|
| EPS Estimate | USD 3.95 |
| Revenue Estimate | $19.41B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-08-31 | USD 3.29 vs est 3.18 ▲ beat |
| 2026-05-31 | USD 3.8 vs est 3.71 ▲ beat |
| 2026-02-28 | USD 2.93 vs est 2.84 ▲ beat |
| 2025-11-30 | USD 3.94 vs est 3.72 ▲ beat |
Source: Nexqual, October 23, 2026 at 08:35 UTC.
Financials & Fundamentals (ACN)
| Total Revenue | $74.18B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +6.20% |
| Gross Margin | +32.05% |
| Operating Margin | +17.83% |
| Profit Margin | +11.28% |
| ROE | +26.02% |
| Debt / Equity | 0.4 |
| Current Ratio | 1.43 |
| Total Cash | $12.84B |
| Total Debt | $13.40B |
| Free Cash Flow (last four quarters to Aug 2026, SEC 10-Q / 10-K) | $11.62B (15.7% of revenue) |
Source: Nexqual, October 23, 2026 at 08:35 UTC.
Financial Health Score (ACN)
Nexqual rates Accenture plc's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 08:35 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 32%, operating 18% (last 12 months) |
| Balance Sheet | Solid — $12.8B cash and investments vs $10.1B debt (Aug 2026, SEC), net cash |
| Cash Flow | Strong — FCF $11.6B (last 4 quarters to Aug 2026, SEC), 16% margin |
| Efficiency | Strong — ROE 26%, ROA 11.0% |
Ownership (ACN)
| Insider Ownership | +0.04% |
|---|---|
| Institutional Ownership | +85.66% |
| Shares Outstanding | 611.94M |
| Float | 589.76M |
| Short % of Float | +3.60% |
Source: Nexqual, October 23, 2026 at 08:35 UTC.
Leadership (ACN)
Accenture plc is led by Julie T. Spellman Sweet, CEO & Chairman, per Nexqual as of October 23, 2026 at 08:35 UTC.
| CEO & Chairman | Julie T. Spellman Sweet |
|---|---|
| Chief Financial Officer | Angie Park |
| Chief Strategy & Services Officer | Manish Sharma |
| Chief Operating Officer | Kate Hogan |
| Chief Technology Officer | Marc Warner |
Major Backers & Investors (ACN)
Notable institutional backers of Accenture plc include Charles Schwab Investment Management, Inc., Charles Schwab, Morgan Stanley, according to Nexqual as of October 23, 2026 at 08:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Charles Schwab Investment Management, Inc. | 3.23% |
| Charles Schwab | 2.2% |
| Morgan Stanley | 1.82% |
| JPMorgan | 1.42% |
| Fidelity | 1.19% |
| Franklin Resources, Inc. | 1.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.3% |
| Vanguard Group | 8.98% |
| State Street | 4.6% |
| Geode Capital | 2.35% |
Source: Nexqual, October 23, 2026 at 08:35 UTC.
From Accenture plc's Latest SEC 10-K Filing (filed 2026-10-16)
Key Strengths & Strategy (as disclosed to the SEC)
- In fiscal 2026, we invested $4.9 billion across 17 strategic acquisitions, $1.0 billion in R&D, and approximately $1.0 billion in learning and professional development, including approximately 46 million training hours.
- Industry and Process – builds industry and process expertise and develops proprietary reinvention methods, AI-enabled ERP approaches, benchmarks, and intelligent operations capabilities.
- Our work with clients in the U.S. federal government is delivered through Accenture Federal Services, a U.S. company and a wholly owned subsidiary of Accenture LLP, and represented approximately 34% of Health & Public Service revenues, 14% of Americas revenues and 7% of total revenues in fiscal 2026.
- Each Reinvention Partner aligns our end-to-end capabilities to a principal enterprise function, buyer or area of the industry value chain.
Legal & Regulatory Risks (Item 1A, quoted)
- Our business could be materially adversely affected if we incur legal liability.
- Government investigations or proceedings related to our diversity, equity and inclusion programs have and may in the future result in financial penalties, sanctions, or restrictions on government contracting, which may adversely affect our results of operations.
- Government contracts are subject to heightened reputational and contractual risks compared to contracts with commercial clients. For example, government contracts and the proceedings surrounding them are often subject to more extensive scrutiny and publicity. Negative publicity, including an allegation of improper or illegal activity, regardless of its accuracy, may adversely affect our reputation.
- Our global operations expose us to numerous and sometimes conflicting legal and regulatory requirements, and violation of these regulations could harm our business.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IBM | International Business Machines | USD 252.11 | ▲ 0.26% |
| INFY | Infosys Limited | USD 13.22 | ▲ 3.69% |
| CTSH | Cognizant Technology Solutions | USD 73.72 | ▲ 6% |
| FISV | Fiserv, Inc. | USD 50.82 | ▲ 5.41% |
| WIT | Wipro Limited | USD 2.19 | ▲ 1.86% |
| BR | Broadridge Financial Solutions, | USD 186.12 | ▲ 4.39% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 08:35 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt